Skip to main content
Premium Trial:

Request an Annual Quote

Natera Sues CareDx Over New Cell-Free DNA Patent

NEW YORK – Natera said on Monday that it has filed a lawsuit against CareDx, claiming the company infringes its US Patent No. 10,526,658.

The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine, such as Natera's Prospera donor-derived cell-free DNA organ transplant test, which competes with CareDx's AlloSure test.

"Natera intends to defend its intellectual property vigorously," said Charles Verhoeven, a counsel for Natera at Quinn Emanuel Uruqhart & Sullivan, in a statement. "CareDx will be held accountable for its blatant lack of respect for Natera's innovation and clear infringement of its intellectual property."

The two companies are also embroiled in other litigation. Last year, CareDx filed two lawsuits against Natera, accusing the firm of false advertisement in one and claiming that it infringes two of its patents relating to cell-free DNA analysis for organ transplant rejection monitoring in the other.